

Biotechnology

December 21, 2023

Guggenheim Grand Rounds: 2023 Wrapped

Guggenheim Therapeutics Research
GStherapeutics@guggenheimpartners.com

Debjit Chattopadhyay, Ph.D.
debjit.chattopadhyay@guggenheimpartners.com
212 823 6584

Vamil Divan, M.D.
vamil.divan@guggenheimpartners.com
212 823 6543

Seamus Fernandez
seamus.fernandez@guggenheimpartners.com
617 859 4637

Kelsey Goodwin
kelsey.goodwin@guggenheimpartners.com
617 859 4621

Eddie Hickman, Ph.D.
eddie.hickman@guggenheimpartners.com
212 518 9904

Michael Schmidt, Ph.D.
michael.schmidt@guggenheimpartners.com
617 859 4636

Yatin Suneja
yatin.suneja@guggenheimpartners.com
212 518 9565

Evan Wang
evan.wang@guggenheimpartners.com
212 651 9756

Key Message: Throughout 2023, we hosted 30+ investor facing expert calls as part of our "Guggenheim Grand Rounds Series" across a range of therapeutic areas and topics of interest to broader biopharma. Key focus areas included **rare diseases & genomic medicine, oncology, neurology & immunology, nephrology & pulmonology, and other rapidly evolving themes including the IRA and Medicare drug price negotiation dynamics.** As we head into 2024, we are wrapping up our year with a comprehensive review of expert call takeaways, including links to the corresponding notes. Happy holidays, and we look forward to resuming our series in 2024!

Oncology

- **Gastrointestinal Stromal Tumors:** Updates on Emerging Therapies and Competitive Positioning of Next-Gen KIT Inhibitors ([link](#))
- **Multiple Myeloma:** Treatment Landscape & Dynamics Heading into ASCO / EHA 2023 ([link](#))
- **Ovarian Cancer:** Emergent Landscape & New Data Heading into ASCO 2023 ([link](#))
- **Bladder Cancer:** Bladder Cancer Thought Leader Shares Enthusiasm for Emerging Profile for JNJ's TAR-200 ([link](#))
- **Lung Cancer:** Evolving NSCLC Treatment Landscape heading into Triple Meeting & ESMO ([link](#))
- **Prostate Cancer:** Emerging Therapies in Prostate Cancer ([link](#))
- **EXEL's Cabometyx IP:** Analysis of EXEL's Cabometyx IP Position and MSN ANDA Trial ([link](#))
- **Multiple Myeloma:** Treatment Landscape & Dynamics Heading into ASH 2023 ([link](#))

Nephrology and Pulmonology

- **Bronchiectasis and MAC Lung Disease:** Upcoming Clinical Data, Current and Future Treatment Landscapes ([link](#))
- **Renal / IgAN:** Takeaways from ERA 2023 and Potential Implications on Chinook Following Novartis Deal Announcement ([link](#))
- **Pulmonary / PAH:** Post-ACC Takeaways from Sotatercept STELLAR Data and the Broader PAH Landscape ([link](#))
- **Autoimmune Pulmonary Alveolar Proteinosis:** Review of SVRA's Molgramostim for aPAP Ahead of Pivotal IMPALA-2 Data ([link](#))
- **IgAN:** Latest Developments in the IgA Nephropathy Space ([link](#))

Neurology and Immunology

- **Alzheimer's Disease:** Alzheimer's Physician + CMS Expert Discussion Ahead of FDA AdCom on ESAIY-BIIB's Leqembi ([link](#))
- **Demodex Blepharitis & Dry Eye Disease:** Current Disease Management, Future XDEMZY Use, and Payer Landscape ([link](#))
- **Friedreich's Ataxia:** RETA's CMC Issues for SKYCLARYS ([link](#))
- **Chronic GvHD:** Updates on Emergent Therapeutics and Treatment Landscape ([link](#))
- **Acute Pain:** Insights into VRTX's VX-548 ([link](#))
- **ACR Review:** Highlights & Key Updates from ACR 2023 ([link](#))

Rare Diseases and Genomic Medicine

- **FCS and Severe Hypertriglyceridemia (sHTG):** Review of FCS and sHTG Space Ahead of IONS's Olezarsen Ph 3 Data ([link](#))
- **Osteogenesis Imperfecta:** RARE's Setrusumab and Osteogenesis Imperfecta Landscape

([link](#))

- **DM1:** Emerging data in the DM1 and DMD Neuromuscular Space ([link](#))
- **Angelman Syndrome:** Insights into Angelman Syndrome and GTX-102 ([link](#))
- **Achondroplasia and other Genetic Causes of Short Stature:** Takeaways from Expert Panel ([link](#))
- **Emerging Hemophilia Treatment Landscape** ([link](#))
- **ATTR-CM:** Takeaways from Expert Panel ([link](#))
- **DM1 and DMD:** Emerging Therapeutic Optionality in the Neuromuscular Diseases ([link](#))
- **SCD:** Perspectives on Casgevy and Lyfgenia ([link](#))

Other Therapeutic Areas and Biopharma Topics

- **Aesthetics:** New Entrants, Entrenched Competitors, and the Economy: The Aesthetic Medicine Market, Daxify, and Fillers, Oh My! ([link](#))
- **Inflation Reduction Act:** Navigating the Inflation Reduction Act - Current Insights and Future Projections ([link](#))
- **NASH / NAFLD and ACLF:** Therapeutics Updates From EASL 2023 Conference ([link](#))
- **Cardiovascular Diseases:** Preview of AHA 2023 Datasets ([link](#))
- **Medicare Drug Price Negotiation:** Updated Insights on Evolving Medicare Pricing Program and Ongoing Lawsuits ([link](#))
- **Medicare Drug Price Negotiation:** Insights on PI Denial, Drug-by-Drug Medicare Opt-Outs, & Pharma's Long Legal Road Ahead ([link](#))

ANALYST CERTIFICATION

By issuing this research report, each Guggenheim Securities, LLC ("Guggenheim Securities") research analyst whose name appears in this report hereby certifies that (i) all of the views expressed in this report accurately reflect the research analyst's personal views about any and all of the subject securities or issuers discussed herein and (ii) no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst.

IMPORTANT DISCLOSURES

The research analyst(s) whose name(s) appear(s) in this report have received compensation based upon various factors, including quality of research, investor client feedback, and Guggenheim Securities, LLC's overall revenue, which includes investment banking revenue.

Please refer to this website for company-specific disclosures referenced in this report: <https://guggenheimsecurities.bluematrix.com/sellside/Disclosures.action>. Disclosure information is also available from Compliance, 330 Madison Avenue, New York, NY 10017.

RATINGS EXPLANATION AND GUIDELINES

BUY (B) - Describes stocks that we expect to provide a total return (price appreciation plus yield) of 10% or more within a 12-month period.

NEUTRAL (N) - Describes stocks that we expect to provide a total return (price appreciation plus yield) of between plus 10% and minus 10% within a 12-month period.

SELL (S) - Describes stocks that we expect to provide a total negative return (price appreciation plus yield) of 10% or more within a 12-month period.

NR - The investment rating and price target have been temporarily suspended. Such suspensions are in compliance with applicable regulations and/or Guggenheim Securities, LLC policies.

CS - Coverage Suspended. Guggenheim Securities, LLC has suspended coverage of this company.

NC - Not covered. Guggenheim Securities, LLC does not cover this company.

Monitor - Describes stocks whose company fundamentals and financials are being monitored, and for which no financial projections or opinions on the investment merits of the company are provided.

Under Review (UR) - Following the release of significant news from this company, the rating has been temporarily placed under review until sufficient information has been obtained and assessed by the analyst.

Guggenheim Securities, LLC methodology for assigning ratings may include the following: market capitalization, maturity, growth/value, volatility and expected total return over the next 12 months. The price targets are based on several methodologies, which may include, but are not restricted to, analyses of market risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group P/E, sum of the parts, net asset value, dividend returns, and return on equity (ROE) over the next 12 months.

Price targets are assigned for Buy- and Sell-rated stocks. Price targets for Neutral-rated stocks are provided at the discretion of the analyst.

Equity Valuation and Risks: For valuation methodology and risks associated with covered companies or price targets for covered companies, please see the most recent company-specific research report at <https://guggenheimlibrary.bluematrix.com/client/library.jsp>, contact the primary analyst or your Guggenheim Securities, LLC representative, or email GSRResearchDisclosures@guggenheimpartners.com.

RATINGS DISTRIBUTIONS FOR GUGGENHEIM SECURITIES:

Rating Category	Count	Percent	IB Serv./ Past 12Mos.	
			Count	Percent
BUY	250	68.49%	44	17.60%
NEUTRAL	107	29.32%	5	4.67%
SELL	8	2.19%	0	0.00%

OTHER DISCLOSURES

This research is for our clients and prospective clients only. This research was prepared by personnel who are associated with both Guggenheim Securities, LLC (a FINRA-registered broker-dealer, "Guggenheim Securities") and Guggenheim Securities Research Services, LLC (an investment adviser, "GSRs," and together with Guggenheim Securities, "Guggenheim"). If you are paying separately for this research, it is being provided to you by GSRs. Otherwise, it is being provided by Guggenheim Securities. Guggenheim does not create tailored or personalized research and all research provided by Guggenheim is impersonal advice. Other than disclosures relating to Guggenheim and our affiliates, this research is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Other than certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate in the research analyst's judgement. Guggenheim Securities conducts a full-service, integrated investment banking and brokerage business. Guggenheim Securities is a member of SIPC (<http://www.sipc.org>). Guggenheim Securities' salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to Guggenheim Securities' clients and our employees trading for our own account that reflect opinions that are contrary to the opinions expressed in this research. Guggenheim and certain of our affiliates conduct an

investment management business, trade for their own accounts, and may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

We and our affiliates, officers, directors, and employees, excluding equity and credit analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this research. We and our affiliates also may sell to or buy from customers on a principal basis the securities described herein. We and our affiliates also do business with, or that relates to, companies covered in Guggenheim research and may have a position in the debt of the company or companies discussed herein.

This research is not an offer to sell or the solicitation of an offer to buy any security. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of investments referred to in this research and the income from them will fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.

This communication does not constitute an offer of Shares to the public in the United Kingdom. No prospectus has been or will be approved in the United Kingdom in respect of the Securities. Consequently, this communication is directed only at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), (iii) high net worth entities falling within Article 49(2) of the Order (iv) and other persons to whom it may lawfully be communicated (all such persons together being referred to as "relevant persons"). Any investment activity to which this communication relates will only be available to, and will only be engaged with, relevant persons. Any person who is not a relevant person, or otherwise in a territory where it is not intended to, or may not, be distributed, should not act or rely on this document or any of its contents.

Copyright © 2023 by Guggenheim Securities, LLC, a FINRA registered broker-dealer, and by Guggenheim Securities Research Services, LLC, an investment adviser (together with, Guggenheim Securities, LLC, "Guggenheim"). All rights reserved. The content of this report is based upon information obtained from sources that Guggenheim generally considers reliable, but Guggenheim makes no representations or warranties with respect to its accuracy, completeness, timeliness, suitability or otherwise, and assumes no responsibility to update it for subsequent events or knowledge. Guggenheim is not responsible for your use of this information.

Guggenheim Securities Equity Research & Equities Teams

Consumer Equity Research

Automotive

Ron Jewsikow 212.823.6581
Ronald.Jewsikow@guggenheimpartners.com

Food Retailers; Consumables Retail/Distribution

John Heinbockel 212.381.4135
John.Heinbockel@guggenheimpartners.com

Hardlines Retail

Steven Forbes, CFA, CPA 212.381.4188
Steven.Forbes@guggenheimpartners.com

Restaurants

Gregory Francfort, CFA 212.518.9182
Gregory.Francfort@guggenheimpartners.com

Retailing/Department Stores & Specialty Softlines

Robert Drbul 212.823.6558
Robert.Drbul@guggenheimpartners.com

Consumer Equities Team

Consumer Sector Specialist

Carey Kaufman 504.299.3424
Carey.Kaufman@guggenheimpartners.com

Power & Energy Transition Equity Research

Energy Technology & Industrial Technology

Joseph Osha, CFA 415.852.6468
Joseph.Osha@guggenheimpartners.com

Power & Utilities

Shahriar Pourreza, CFA 212.518.5862
Shahriar.Pourreza@guggenheimpartners.com

Technology & Media Equity Research

Entertainment & Digital Media

Michael Morris, CFA 804.253.8025
Michael.Morris@guggenheimpartners.com

IT Services

Jonathan Lee 212.518.5388
Jonathan.Lee@guggenheimpartners.com

Media & Live Entertainment

Curry Baker 804.253.8029
Curry.Baker@guggenheimpartners.com

Software

John DiFucci 212.518.9670
John.DiFucci@guggenheimpartners.com

Howard Ma 512.354.3458
Howard.Ma@guggenheimpartners.com

Raymond McDonough, CFA 212.518.9704
Raymond.McDonough@guggenheimpartners.com

Technology & Media Equities Team

TMT Sector Specialist

Seth Ostrie 212.518.9547
Seth.Ostrie@guggenheimpartners.com

Healthcare Equity Research

Biotechnology

Debjit Chattopadhyay, Ph.D. 212.823.6584
Debjit.Chattopadhyay@guggenheimpartners.com

Kelsey Goodwin 617.859.4621
Kelsey.Goodwin@guggenheimpartners.com

Eddie Hickman, Ph.D. 212.518.9904
Eddie.Hickman@guggenheimpartners.com

Michael Schmidt, Ph.D. 617.859.4636
Michael.Schmidt@guggenheimpartners.com

Yatin Suneja 212.518.9565
Yatin.Suneja@guggenheimpartners.com

Diagnostics & Life Sciences Tools

Subbu Nambi, Ph.D. 617.859.4609
Subbu.Nambi@guggenheimpartners.com

Global Biopharmaceuticals

Vamil Divan, M.D. 212.823.6543
Vamil.Divan@guggenheimpartners.com

Seamus Fernandez 617.859.4637
Seamus.Fernandez@guggenheimpartners.com

Evan Wang 212.651.9756
Evan.Wang@guggenheimpartners.com

Healthcare IT & Services

Jack Wallace 212.518.9620
Jack.Wallace@guggenheimpartners.com

Healthcare Equities Team

Healthcare Sector Specialist

Whitney Wolfe 212.518.9630
Whitney.Wolfe@guggenheimpartners.com

Equities Management

Stefano Natella, Head of Equities 212.292.4700
Jeffrey Cohen, Head of Sales 212.292.4762
Dante Ferrarie, Head of Trading 212.518.3331
Craig Peckham, Head of Research 212.292.4765

Sales and Trading Offices

New York 212.292.4700
San Francisco 415.852.6451
Boston 617.859.4626
Richmond 804.253.8052